MoonLake’s nanobody boosts PsA indication hopes after Phase III success

Phase 3positivePositive

AI Analysis

Summary

MoonLake's nanobody achieved Phase III success in psoriatic arthritis (PsA), following an earlier successful readout in hidradenitis suppurativa (HS) in 2026.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III success in PsA indication

Importance:7/10

Sentiment:

0.75

Phase IIIpositive datananobodyPsAHS

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 11, 2026 2:50 PM

Read Original